The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Caramelo, Belen
Munoz Unceta, Nerea
Freire, Javier
Varela, Ignacio
Martin, David
Del Carmen, Sofia
Azueta, Ainara
Diaz, Pilar
Garcia-Berbel, Pilar
Sagastibelza Marinelarena, Naiara
Rey-Cardenas, Macarena
Castellano, Daniel
Climent, Miguel Angel
Puente, Javier
Irure, Juan
Revuelta, Laura
Genre, Fernanda
Cacho, Diego
Gomez, Javier
Duran, Ignacio
机构：
[1] IDIVAL, Inst Invest Valdecilla, Santander, Cantabria, Spain
[2] Hosp Univ Marques de Valdecilla, Santander, Cantabria, Spain
[3] IBBTEC, Inst Biomed & Biotecnol Cantabria, Santander, Cantabria, Spain
[4] Hosp Donostia, San Sebastian, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
[6] Hosp Univ 12 Octubre, Serv Oncol Med, Madrid, Spain
[7] Inst Valenciano Oncol, Valencia, Spain
[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain
[9] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Cantabria, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-11076; 261-566-9718-9794; 298-4768-3691-2722-5055; 283-2494; 283-183-138-12268; 298-4768-12362; 261-492-5651-9270-5657; 6; 5; 3; 2; 38092-27449; 38092-25821; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：668 / 668
页数：1
相关论文
共 50 条
  • [41] Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Stecca, Carlos
    Selvarajah, Shamini
    Jiang, Di Maria
    Abdeljalil, Osama
    Zhang, Tong
    Bedard, Philippe L.
    Hansen, Aaron Richard
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
    Ruiz-Banobre, J.
    Molina-Diaz, A.
    Fernandez-Calvo, O.
    Fernandez-Nunez, N.
    Medina-Colmenero, A.
    Santome, L.
    Lazaro-Quintela, M.
    Mateos-Gonzalez, M.
    Garcia-Cid, N.
    Lopez-Lopez, R.
    Vazquez, S.
    Anido-Herranz, U.
    ESMO OPEN, 2021, 6 (02)
  • [43] TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma
    Nishiyama, Hiroyuki
    Yonese, Junji
    Kawahara, Takashi
    Matsumoto, Ryuji
    Miyake, Hideaki
    Matsubara, Nobuaki
    Uemura, Hiroji
    Eto, Masatoshi
    Azuma, Haruhito
    Obara, Wataru
    Terai, Akito
    Fukasawa, Satoshi
    Suekane, Shigetaka
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 532 - 540
  • [44] Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a targeted literature review (TLR).
    Kearney, Mairead
    Janssens, Rosanne
    Quaife, Matt
    Trapali, Myrto
    Thomas, Caitlin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [45] Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The US physician PARADIGM study.
    Gupta, Shilpa
    Su, Cathy
    Bhanegaonkar, Abhijeet
    Gupta, Shaloo
    Thakkar, Sheena
    Mackie, deMauri S.
    Devgan, Geeta
    Katzenstein, Howard
    Liu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [46] Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
    Makrakis, Dimitrios
    Talukder, Rafee
    Dawsey, Scott
    Carril, Lucia
    Stewart, Tyler F.
    Morales-Barrera, Rafael
    Park, Joseph J.
    Fulgenzi, Claudia Angela Maria
    Murgic, Jure
    Vather-Wu, Naomi
    de Kouchkovsky, Ivan
    Devitt, Michael Edward
    Di Lorenzo, Giuseppe
    Gupta, Kavita
    Tripathi, Nishita
    Zakopoulou, Roubini
    Tripathi, Abhishek
    Lu, Eric
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in real-world setting.
    Lynn, David
    Dawsey, Scott
    Hobeika, Charbel
    Patgunarajah, Ubenthira
    Pramod, Nikhil
    Wei, Wei
    Nair, Monica
    Maroli, Kimberly
    Martin, Allison
    Ornstein, Moshe Chaim
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Nizam, Amanda
    Bonham, Amanda
    Mian, Omar Y.
    Pavicic, Paul G., Jr.
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
    Fontes, Mariane S.
    de Almeida, Daniel Vargas Pivato
    Cavalin, Clarissa
    Tagawa, Scott T.
    ONCOTARGETS AND THERAPY, 2022, 15 : 1531 - 1542
  • [49] Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
    Lista, A. Gomez de Liano
    Necchi, A.
    Lavaud, P.
    Carles Galceran, J.
    Castellano, D.
    Ravaud, A.
    Duran, I.
    van Dijk, N.
    Giannatempo, P.
    Loriot, Y.
    Morales Barrera, R.
    De Velasco Oria De Rueda, G.
    Lefort, F.
    Martinez Bernal, G.
    Raggi, D.
    Gross-Goupil, M.
    Powles, T.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC).
    Sahu, Kamal Kant Kant
    Tripathi, Nishita
    Chigarira, Beverly
    Sayegh, Nicolas
    Thomas, Vinay Mathew
    Li, Haoran
    Jo, Yeonjung
    Gebrael, Georges
    Iyer, Puja
    Nussenzveig, Roberto
    Agarwal, Neeraj
    Maughan, Benjamin L.
    Gupta, Sumati
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345